Medpace Holdings Inc. (MEDP) Stock Falls on Q1 2026 Earnings

Medpace Holdings Inc. (MEDP) reported first-quarter 2026 results with total revenue of $706.6 million, up 26.5% year-over-year and slightly below the consensus revenue estimate of $711.6 million.

Gross profit: $196.3 million (up 10.08% YoY).

Operating profit: $141.5 million (up 24.65% YoY).

Net income attributable to common shareholders: $123.9 million (up 8.09% YoY).

Diluted earnings per share: 4.28 (up 16.62% YoY; consensus was 3.96).

Cash flow and balance-sheet highlights show operating cash flow of $151.8 million (up 20.62% YoY) and capital spending of $6.8 million (down 31.82% YoY). Cash and cash equivalents increased to $652.7 million, while total liabilities stood at $1.53 billion (up 17.45% YoY).

Cost of sales: $510.3 million (up 34.21% YoY).

EPS beat: reported diluted EPS of 4.28 versus the estimate of 3.96.

Market reaction: shares were down 14.74% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Medpace Holdings Inc. Insider Trading Activity

Medpace Holdings Inc. insiders have traded $MEDP stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.

Here’s a breakdown of recent trading of $MEDP stock by insiders over the last 6 months:

AUGUST J. TROENDLE (CEO) has made 0 purchases and 15 sales selling 278,418 shares for an estimated $167,599,756.
JESSE J GEIGER (President) has made 0 purchases and 4 sales selling 76,238 shares for an estimated $41,107,589.
SUSAN E BURWIG (Exec. VP, Operations) has made 0 purchases and 3 sales selling 40,000 shares for an estimated $24,283,020.
STEPHEN P EWALD (General Counsel & Corp. Secy.) sold 15,230 shares for an estimated $9,120,485
ROBERT O. KRAFT sold 6,472 shares for an estimated $3,830,453
FRED B JR DAVENPORT sold 5,972 shares for an estimated $3,474,987
KEVIN M. BRADY (CFO & Treasurer) sold 3,000 shares for an estimated $1,771,050

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Medpace Holdings Inc. Hedge Fund Activity

We have seen 363 institutional investors add shares of Medpace Holdings Inc. stock to their portfolio, and 354 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AQR CAPITAL MANAGEMENT LLC added 324,293 shares (+31.6%) to their portfolio in Q4 2025, for an estimated $182,139,163
MAWER INVESTMENT MANAGEMENT LTD. removed 239,472 shares (-37.0%) from their portfolio in Q4 2025, for an estimated $134,499,448
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 200,597 shares (-63.1%) from their portfolio in Q4 2025, for an estimated $112,665,305
FMR LLC added 195,907 shares (+2507.1%) to their portfolio in Q4 2025, for an estimated $110,031,166
FRANKLIN RESOURCES INC added 183,645 shares (+158.6%) to their portfolio in Q4 2025, for an estimated $103,144,214
VULCAN VALUE PARTNERS, LLC removed 152,866 shares (-76.4%) from their portfolio in Q4 2025, for an estimated $85,857,188
FINDLAY PARK PARTNERS LLP removed 127,900 shares (-42.3%) from their portfolio in Q4 2025, for an estimated $71,835,035

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Medpace Holdings Inc. Congressional Stock Trading

Members of Congress have traded $MEDP stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $MEDP stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR has traded it 3 times. They made 2 purchases worth up to $30,000 on 02/26, 01/29 and 1 sale worth up to $15,000 on 01/16.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $50,000 on 01/15.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Medpace Holdings Inc. Analyst Ratings

Wall Street analysts have issued reports on $MEDP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 02/13/2026

To track analyst ratings and price targets for Medpace Holdings Inc., check out Quiver Quantitative's $MEDP forecast page.

Medpace Holdings Inc. Price Targets

Multiple analysts have issued price targets for $MEDP recently. We have seen 7 analysts offer price targets for $MEDP in the last 6 months, with a median target of $522.0.

Here are some recent targets:

Luke Sergott from Barclays set a target price of $500.0 on 03/06/2026
Ryan Halsted from RBC Capital set a target price of $522.0 on 03/03/2026
Charles Rhyee from TD Cowen set a target price of $419.0 on 02/18/2026
David Windley from Jefferies set a target price of $560.0 on 02/13/2026
Michael Cherny from Leerink Partners set a target price of $485.0 on 02/11/2026
Jailendra Singh from Truist Securities set a target price of $539.0 on 02/11/2026
Sean Dodge from BMO Capital set a target price of $600.0 on 11/13/2025